Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

NCT05904080 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

NIH

Sponsor class

Conditions

Metastatic Nasopharyngeal Carcinoma
Recurrent Nasopharyngeal Carcinoma
Stage IV Nasopharyngeal Carcinoma AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Cabozantinib S-malate
PROCEDURE: Computed Tomography
BIOLOGICAL: Ipilimumab
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Institute (NCI)